CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
Original article

First participant dosed in Ionis’ Phase I-II ASCEND study

Phase 1ION337Positive
AI Analysis

Summary

Ionis Pharmaceuticals has initiated dosing of the first patient in its Phase I-II ASCEND trial evaluating ION337 for pediatric Dravet syndrome patients.

Clinical Trial Data

Phase

Phase I-II

Importance:4/10
Sentiment:
0.50
trial startDravet syndromerare diseaseantisense oligonucleotide
Related Companies

Read the original article

Published by Clinical Trials Arena on July 14, 2026 7:46 AM

Read Original